Administration of Yunnan Baiyao or Xingnaojing in patients with moderate-to-severe traumatic brain injury and craniotomy
Grant
US12582691B2
Kind: B2
Mar 24, 2026
Assignee
Lotus Biotech.com LLC
Inventors
Guoqiang Xing, Xiaodong Ma
Abstract
Clinically validated methods of administering Yunnan Baiyao or Xingnaojing can improve postoperative recovery and long-term clinical prognosis of patients with moderate-to-severe traumatic brain injury (TBI) and emergency craniotomy. Both medicinal methods are useful for minimizing or inhibiting the adverse impacts of secondary injury, oxidative damage and neuroinflammation associated with TBI, spinal cord injury, craniotomy/craniectomy, cerebral hemostasis and hemorrhage, coagulopathy, stroke, neural injury and neuroinflammation, and for promoting the long-term functional recovery and well-being of the patients with the afore-mentioned diseases.
CPC Classifications
A61K 36/9066
A61K 35/55
A61K 36/258
A61K 36/744
A61K 45/06
A61P 7/04
A61P 29/00
Filing Date
2022-07-12
Application No.
17812171
Claims
7